Paclitaxel Teva 6 mg/ml concentrado para solución para perfusión EFG

“Phase II clinical trial of chemotherapy + atezolizumab for stage IIIA and IIIB non-small cell lung cancer followed by atezolizumab as adjuvant treatment after surgery and atezolizumab for non-resected patients after chemoradiotherapy” ATHENEA

A Phase II, Multicenter, Randomized Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (ERBIOTAX)

Phase II clinical trial with an adaptive design according to response to cemiplimab monotherapy using ctDNA and subsequent treatment with chemotherapy (CT) and cemiplimab or cemiplimab monotherapy in first line advanced NSCLC patients. PALACE GECP 22/01

¨Neoadjuvant phase II study of pembrolizumab and carboplatin plus paclitaxel for stage I triple-negative breast cancer (The TELESCOPE study)¨.

Phase II randomized clinical trial for evaluating the safety and feasibility of fecal microbiota transplant (FMT) in stage II-III non-small cell lung cancer (NSCLC) patients, using immune checkpoint inhibitors (ICI) responders as donors. MIGRANT GECP 24/02